Signaling a Brighter Future for Patients with Life-Threatening Diseases

About Complexa

Complexa Inc. is a clinical stage biopharmaceutical company focused on transforming the lives of patients burdened with severe and life-threatening fibrosis and inflammatory diseases. The Company is developing medicines with the goal of preventing and repairing tissue injury and reversing fibrosis and inflammation. Our focus is on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. 


June 03, 2020

Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease

February 07, 2020

Complexa Names Elisabeth Leiderman, MD, MBA, Chief Business Officer

Please reload